AlzeCure Pharma
STOCKHOLM, SE / ACCESSWIRE / November 04, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company's latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021 . The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day 2021 on November 11
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/671149/AlzeCure-Presents-at-Redeye-Life-Science-Day-2021-on-November-11
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Preservica Integrates Active Digital Preservation with Microsoft 365 Archive12.11.2025 15:00:00 CET | Press release
BOSTON, MA AND OXFORD, UK / ACCESS Newswire / November 12, 2025 / Preservica is expanding its ongoing collaboration with Microsoft with a new integration to bring embedded Active Digital Preservation™ to Microsoft 365 Archive. The latest Preserve365® integration offers Microsoft customers additional flexibility and control over the management of long-term SharePoint content. With Preservica's embedded Active Digital Preservation software, IT and Information Governance (IG) teams can now seamlessly archive and actively preserve high-value SharePoint sites - such as completed projects containing long-term regulatory, legal, or operational data. This protects critical data from obsolescence, ensuring long-term records are always immediately accessible in trusted, readable formats to enable business teams to respond quickly and confidently to audits, legal proceedings, maintenance continuity and AI-driven initiatives. Better together: Optimizing cost and compliance for long-term content. M
Karbon-X and Hockey Canada Partner to Make Sustainability Part of Canada's Game12.11.2025 15:00:00 CET | Press release
The Canadian-based climate-solutions company joins forces with Hockey Canada to deliver measurable sustainability impact across national tournaments and community programs. CALGARY, AB / ACCESS Newswire / November 12, 2025 / Following Hockey Canada's announcement earlier this week, Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to confirm its new partnership with Hockey Canada, becoming the organization's Official Sustainability Partner and advancing verified sustainability initiatives across one of the nation's most celebrated sports. The multi-year partnership integrates verified, measurable sustainability programs into Hockey Canada's national tournaments and grassroots registration, empowering players, fans, and communities across the country to take part in meaningful environmental initiatives. Together, the two organizations are uniting national pride with environmental purpose, showing that every game can leave a positive impact. Through the partnership, sele
Loar Holdings Inc. Reports Q3 2025 Record Results and Upward Revisions to 2025 Outlook and Full Year 2026 Outlook12.11.2025 14:30:00 CET | Press release
WHITE PLAINS, NY / ACCESS Newswire / November 12, 2025 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reports record results for the third quarter of 2025, upward revisions to 2025 outlook, and full year 2026 outlook. "The strong tailwinds of secular growth in commercial passenger traffic, immense backlogs at the airframe manufacturers, and global demand for defense products once again led us to a record quarter," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. Third Quarter 2025 Net sales of $126.8 million, up 22.4% compared to the prior year's quarter. Net income of $27.6 million, up 218.9% compared to the prior year's quarter. Diluted earnings per share of $0.29, up 222.2% compared to the prior year's quarter. Adjusted EBITDA of $49.1 million, up 28.9% compared to the prior year's quarter. Net income margin for the quarter improved to 21.8% compared to the prior year's quarter of 8.4%. Adjusted EBITDA Margin for
Camino Announces C$5.6 Million Investment with Strategic Investors12.11.2025 12:00:00 CET | Press release
Not for distribution to United States newswire services or for release publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. VANCOUVER, BC / ACCESS Newswire / November 12, 2025 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that it is arranging a non-brokered private placement to raise total gross proceeds of approx. C$5.6 Million (the "Financing"). The Financing will consist of the issuance of 15,554,666 common shares of the Company (each a "Share") at a price per Share of C$0.36. Participants in the financing will include two significant new shareholders, EMX Royalty Corp. ("EMX") and Continental General Insurance Company ("CGIC"). Based in Austin, Texas, CGIC is one of the largest shareholders of Camino's partner, Nittetsu Mining. CGIC is a life and health insurance company founded in 1961, and is an active investor in producing and development-stage mining asse
Xsens Announces New Xsens Link for Motion Capture Across Humanoid Robotics, Health, Sports, and Entertainment12.11.2025 10:00:00 CET | Press release
Next-Generation motion capture from Xsens combines smarter sensors, seamless connectivity, and adaptive design to deliver precise, real-world motion data. ENSCHEDE, NL / ACCESS Newswire / November 12, 2025 / Xsens, a Movella brand and world leader in inertial motion capture technology, today announced the launch of the next-generation Xsens Link, an all-new motion capture system that redefines accuracy, usability, and versatility for users across industries. Redesigned from the ground up, the new Xsens Link delivers superior comfort, smarter data output, and minimal maintenance, empowering users to capture motion data with unprecedented speed and fidelity - whether in a robotics lab, film studio, or on the training field. "We've taken everything our customers love about Xsens and built the next generation around comfort, consistency, and flexibility," says Dennis Kloppenburg, product manager at Xsens. "From animators to athletes to robotics developers and researchers, The new Link deli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom